| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 523 | 571 | 558 | 583 | 745 | 845 | 826 | 820 | 1,029 | 1,330 | 1,757 | 2,048 |
| Expenses | 529 | 547 | 507 | 525 | 657 | 711 | 678 | 719 | 838 | 1,111 | 1,462 | 1,732 |
| EBITDA | -6 | 23 | 51 | 59 | 88 | 134 | 148 | 101 | 191 | 219 | 295 | 316 |
| Operating Profit % | -2 % | 3 % | 7 % | 8 % | 10 % | 15 % | 17 % | 11 % | 16 % | 14 % | 15 % | 14 % |
| Depreciation | 15 | 17 | 16 | 15 | 15 | 19 | 20 | 17 | 16 | 15 | 40 | 46 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Profit Before Tax | -21 | 6 | 36 | 44 | 73 | 114 | 127 | 83 | 134 | 220 | 156 | 268 |
| Tax | 0 | 1 | 15 | 18 | 18 | 42 | 34 | 21 | 35 | 58 | 41 | 76 |
| Net Profit | -21 | 5 | 20 | 26 | 54 | 72 | 93 | 62 | 99 | 162 | 116 | 199 |
| EPS in ₹ | -8.34 | 2.10 | 8.00 | 10.40 | 21.80 | 28.90 | 37.30 | 24.60 | 39.70 | 64.60 | 46.30 | 79.70 |
AstraZeneca Pharma
AstraZeneca Pharma
9,153.00
-30.00
(-0.33%)
Key Fundamentals
Market Cap
22,957.50 Cr
EPS
46.30
PE Ratio
115.54
Dividend Yield
0.35 %
Industry
Healthcare 52 Week High
10,691.00
52 Week Low
6,220.00
PB Ratio
28.80
Debt to Equity
0.03
Sector
Pharmaceuticals Actual
Company News
View All News
AstraZeneca Pharma India announced that Company Secretary Manasa R has resigned to pursue career opportunities outside the organization, with her last working day being November 28, 2025. The company is searching for a suitable replacement. Additionally, AstraZeneca reported quarterly results showing total income from operations of Rs 5,652.6 million, net profit after tax of Rs 542.2 million, and earnings per share of Rs 21.69. The company has ceased operations at its manufacturing site and is in the process of selling assets related to the manufacturing facility, which have been classified as assets held for sale.
AstraZeneca Pharma delivered strong quarterly results with net profit rising to 542 million rupees from 384 million rupees year-over-year. Revenue grew significantly to 5.6 billion rupees compared to 4.08 billion rupees in the same period last year. EBITDA increased to 752 million rupees from 524 million rupees, while EBITDA margin improved to 13.45% from 12.84% year-over-year.
AstraZeneca Pharma India Limited announced the launch of Sodium Zirconium Cyclosilicate powder (Lokelma) for oral suspension in November 2025. The company received Import and Marketing Permission from the Drugs Controller General of India in March 2025. The 5g oral suspension product is indicated for treating hyperkalaemia in adult patients. The company had previously obtained regulatory approval for both 5g and 10g formulations but is launching the 5g version first.
View more
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,757.10 | #1 4,16,860.50 | 39.72 | #1 54,729.00 | 9.71 | #1 10,980 | 2.89 | 71.24 | |
6,511.50 | 1,75,036.70 | 70.39 | 9,712.00 | 18.67 | 2,191 | 35.10 | 49.85 | |
3,831.80 | 1,29,492.60 | 60.50 | 11,539.40 | 6.99 | 1,911 | 30.46 | 70.96 | |
1,532.10 | 1,23,247.10 | 22.68 | 28,409.50 | 7.12 | 5,291 | 3.71 | 48.07 | |
1,246.00 | 1,03,066.50 | #1 17.96 | 33,741.20 | 16.73 | 5,725 | -0.38 | 52.75 | |
944.45 | 95,003.60 | 18.89 | 23,511.00 | 18.55 | 4,615 | 34.60 | 37.46 | |
2,055.30 | 93,767.10 | 21.57 | 22,909.50 | 13.74 | 3,306 | #1 72.75 | 65.62 | |
2,267.10 | 93,159.60 | 52.49 | 12,744.20 | #1 20.90 | 2,007 | -21.05 | 33.43 | |
1,222.50 | 70,288.60 | 20.71 | 32,345.60 | 9.43 | 3,484 | 3.81 | 73.28 | |
5,722.50 | 68,456.90 | 28.39 | 13,458.30 | 3.70 | 2,216 | 10.98 | 64.53 |
Growth Rate
Revenue Growth
32.07 %
Net Income Growth
-28.36 %
Cash Flow Change
134.52 %
ROE
-33.80 %
ROCE
-36.77 %
EBITDA Margin (Avg.)
1.76 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 412 | 403 | 416 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 |
| Fixed Assets | 101 | 97 | 87 | 76 | 75 | 72 | 81 | 75 | 69 | 67 | 64 |
| Current Assets | 263 | 267 | 252 | 321 | 405 | 542 | 619 | 706 | 836 | 933 | 1,342 |
| Capital Work in Progress | 12 | 6 | 5 | 4 | 7 | 24 | 4 | 2 | 1 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 298 | 299 | 324 | 382 | 480 | 611 | 690 | 780 | 915 | 1,011 | 1,454 |
| Total Liabilities | 412 | 403 | 416 | 461 | 562 | 706 | 775 | 857 | 985 | 1,078 | 1,518 |
| Current Liabilities | 260 | 234 | 190 | 207 | 259 | 327 | 304 | 333 | 384 | 357 | 703 |
| Non Current Liabilities | 1 | 13 | 2 | 7 | 2 | 15 | 15 | 13 | 12 | 9 | 45 |
| Total Equity | 151 | 156 | 223 | 247 | 301 | 364 | 456 | 511 | 589 | 712 | 770 |
| Reserve & Surplus | 146 | 151 | 218 | 242 | 296 | 359 | 451 | 506 | 584 | 707 | 765 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | -64 | 53 | 38 | -1 | 59 | -90 | 269 | 96 | 52 | 5 | 31 |
| Investing Activities | -19 | -4 | 0 | -9 | 4 | -171 | 173 | 5 | 18 | 22 | 31 |
| Operating Activities | -46 | 57 | 38 | 9 | 55 | 87 | 105 | 101 | 58 | 28 | 65 |
| Financing Activities | 0 | -1 | 0 | 0 | 0 | -6 | -9 | -10 | -25 | -44 | -66 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 |
| Promoter | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % | 75.00 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 2.69 % | 0.00 % | 2.74 % | 2.79 % | 2.90 % | 2.93 % | 2.89 % | 3.03 % | 2.74 % |
| DIIs | 0.83 % | 0.94 % | 0.96 % | 1.00 % | 1.02 % | 1.10 % | 1.12 % | 1.44 % | 1.42 % | 1.93 % | 2.43 % | 2.75 % | 3.78 % | 5.01 % | 5.10 % | 5.22 % | 4.65 % | 4.56 % | 5.26 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 19.53 % | 19.72 % | 19.69 % | 19.44 % | 19.06 % | 18.62 % | 18.54 % | 18.56 % | 18.46 % | 18.12 % | 17.44 % | 17.09 % | 16.33 % | 15.00 % | 14.77 % | 14.62 % | 15.16 % | 15.18 % | 14.39 % |
| Others | 4.64 % | 4.34 % | 4.34 % | 4.57 % | 4.92 % | 5.28 % | 5.34 % | 5.01 % | 5.12 % | 4.95 % | 2.44 % | 5.15 % | 2.15 % | 2.20 % | 2.23 % | 2.24 % | 2.31 % | 2.23 % | 2.61 % |
| No of Share Holders | 0 | 63,753 | 68,077 | 66,444 | 62,183 | 57,760 | 53,980 | 49,085 | 42,146 | 38,946 | 32,380 | 29,032 | 29,418 | 27,169 | 27,615 | 27,322 | 32,466 | 34,378 | 32,914 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 1 | 2 | 10 | 16 | 24 | 32 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.08 | 0.31 | 0.3 | 0.28 | 0.35 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 20 Aug 2021 |  Dividend | ₹ 2.00 /share | 18 Aug 2021 | 3,406.35 | 3,101.65 |
| 08 Jul 2022 | Dividend | ₹ 8.00 /share | 07 Jul 2022 | 2,635.15 | 2,898.90 |
| 08 Aug 2022 |  Annual General Meeting | NA | 08 Aug 2022 | 2,982.60 | 3,079.00 |
| 14 Jul 2023 | Dividend | ₹ 16.00 /share | 14 Jul 2023 | 3,253.00 | 3,767.35 |
| 05 Jul 2024 | Dividend | ₹ 24.00 /share | 05 Jul 2024 | 6,011.75 | 7,120.15 |
| 08 Aug 2024 | Annual General Meeting | NA | 08 Aug 2024 | 6,610.75 | 7,090.80 |
| 13 Nov 2024 |  Quarterly Result Announcement | NA | 13 Nov 2024 | 7,155.25 | 7,410.50 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 6,920.30 | 7,535.10 |
| 30 May 2025 | Quarterly Result Announcement | NA | 30 May 2025 | 7,920.85 | 7,918.50 |
| 18 Jul 2025 | Dividend | ₹ 32.00 /share | 18 Jul 2025 | 7,918.50 | 9,386.25 |
| 14 Aug 2025 | Quarterly Result Announcement | NA | 14 Aug 2025 | 8,953.35 | 8,416.50 |
| 14 Aug 2025 | Annual General Meeting | NA | 14 Aug 2025 | 8,832.65 | 8,416.50 |
| 07 Nov 2025 | Quarterly Result Announcement | NA | 07 Nov 2025 | 9,302.50 | 9,182.50 |
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer4 days ago
4 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release6 days ago
6 days agoOutcome Of The Board Meeting Held On Friday November 7 20257 days ago
7 days agoBoard Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Friday November 7 2025Oct 27, 2025
Oct 27, 2025Launch Of Sodium Zirconium Cyclosilicate Powder For Oral Suspension 5G (Lokelma)Oct 15, 2025
Oct 15, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 09, 2025
Oct 09, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Oct 03, 2025
Oct 03, 2025Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 19, 2025
Sep 19, 2025Closure of Trading WindowSep 12, 2025
Sep 12, 2025Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Sep 12, 2025
Sep 12, 2025Disclosure under Regulation 30A of LODRSep 12, 2025
Sep 12, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Sep 10, 2025
Sep 10, 2025Disclosure under Regulation 30A of LODRSep 02, 2025
Sep 02, 2025Disclosure under Regulation 30A of LODRSep 01, 2025
Sep 01, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 19, 2025
Aug 19, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportAug 18, 2025
Aug 18, 2025Shareholder Meeting / Postal Ballot-Outcome of AGMAug 14, 2025
Aug 14, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseAug 14, 2025
Aug 14, 2025Outcome Of The Board Meeting Held On Thursday August 14 2025Aug 14, 2025
Aug 14, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Aug 12, 2025
Aug 12, 2025Launch Of Eculizumab (Soliris)Aug 06, 2025
Aug 06, 2025Clarification On News Item Appearing In Https://Www.Moneycontrol.ComAug 01, 2025
Aug 01, 2025Clarification sought from AstraZeneca Pharma India LtdAug 01, 2025
Aug 01, 2025Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday August 14 2025Jul 24, 2025
Jul 24, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJul 24, 2025
Jul 24, 2025Business Responsibility and Sustainability Reporting (BRSR)Jul 22, 2025
Jul 22, 2025Notice Of 46Th Annual General MeetingJul 22, 2025
Jul 22, 2025Reg. 34 (1) Annual Report.Jul 22, 2025
Jul 22, 2025Communication To The Shareholders W.R.T. TDS On DividendJul 21, 2025
Jul 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 16, 2025
Jul 16, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jul 14, 2025
Jul 14, 2025Disclosure under Regulation 30A of LODRJul 11, 2025
Jul 11, 2025Record Date For Payment Of Final DividendJul 11, 2025
Jul 11, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015Jul 01, 2025
Jul 01, 2025Determination Of Materiality - Details Of Key Managerial PersonnelJul 01, 2025
Jul 01, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jun 20, 2025
Jun 20, 2025Closure of Trading WindowJun 13, 2025
Jun 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJun 09, 2025
Jun 09, 2025Announcement under Regulation 30 (LODR)-Resignation of Managing DirectorJun 09, 2025
Jun 09, 2025Disclosure under Regulation 30A of LODRJun 07, 2025
Jun 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJun 02, 2025
Jun 02, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 30, 2025
May 30, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Appointment Of Secretarial AuditorMay 30, 2025
May 30, 2025Outcome Of The Board Meeting Held On Friday May 30 2025
May 30, 2025
May 30, 2025Board Meeting Outcome for Recommendation Of Dividend For The Financial Year 2024-25May 30, 2025
May 30, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015May 30, 2025
May 30, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015May 29, 2025
May 29, 2025Mutual Fund Holdings
UTI MNC Fund Direct-Growth 
ICICI Prudential Multicap Fund Direct Plan-Growth 
Baroda BNP Paribas Health and Wellness Fund Direct-Growth 
Bandhan Innovation Fund Direct-Growth 
Samco Multi Asset Allocation Fund Direct-Growth 
Edelweiss Nifty500 Multicap Momentum Quality 50 Index Fund Direct-Growth 
Nippon India Nifty Smallcap 250 Index Fund Direct - Growth 
JioBlackRock Nifty Smallcap 250 Index Fund Direct - Growth 
DSP Nifty Smallcap250 Quality 50 Index Fund Direct - Growth 
Motilal Oswal Nifty Smallcap 250 Index Fund Direct - Growth 
HDFC Nifty Smallcap 250 Index Fund Direct-Growth 
Navi Nifty Smallcap250 Momentum Quality 100 Index Fund Direct - Growth 
SBI Nifty 500 Index Fund Direct-Growth Technical Indicators
RSI(14)
Neutral 47.65
ATR(14)
Volatile 244.46
STOCH(9,6)
Neutral 25.12
STOCH RSI(14)
Oversold 14.91
MACD(12,26)
Bearish -40.49
ADX(14)
Weak Trend 20.39
UO(9)
Bearish 47.48
ROC(12)
Downtrend And Accelerating -1.38
WillR(14)
Neutral -65.28
About AstraZeneca Pharma
AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for heart failure and chronic kidney disease, Imfinzi for biliary tract carcinoma, Lynparza for breast cancer, and oral antidiabetic drugs like Onglyza and Kombiglyze. AstraZeneca Pharma India is a subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which is indirectly owned by AstraZeneca PLC, United Kingdom. The company has manufacturing facilities in Bangalore and has expanded its R&D presence in India.
Website
Chairperson NameShilpa Divekar Nirula
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
